The WHO and NIH disagree about Remdesivir which I think is alarming.
UK, Europe have approved it and the USA has only approved it for emergency use. It was used on Trump (however one feels about him is not important here IMO),
Dr. Andre Kalil, a University of Nebraska infectious disease specialist who helped lead the U.S. remdesivir study, said the WHO one was poorly designed, which makes its conclusions less reliable. Patients and doctors knew what treatment they were using, there was no placebo infusion to help avoid biased reporting of risks or benefits, there was little information about the severity of patients’ symptoms when treatments began and a lot of missing data, he said.
WHO study finds remdesivir didn't help COVID-19 patients
When I read this article I was alarmed by the emphasis that they placed on the drug cost instead of whether the drug works. The entire population of the world is not going to die from Covid prior to the vaccine (at least).
Why not give it to the people (all over the world) that develop the virus?
Governments have a lot of purchasing power plus there are people like Bill Gates and Bill Clinton. Those 2 helped to bring down the cost of HIV drugs to a very low cost. There are foundations and the WHO that could help fund it.
America is about to change administrations and no one knows whether the FDA will decide that it can't be administered in the USA.
I am not blaming anyone at all. I am just very concerned.
There is so much to unravel here. And MSM, nor I here in one post, can give all the background and the meaning may be misinterpreted. As Fauci says, this isn't a replacement for public health measures, it's a complement as are the vaccines.
The rationale for the WHO study was not the same as the double blind placebo trials such as was in NEJM, and weren't meant to compare to such studies. They (WHO) at the time were purposefully doing baseline studies to compare treatments of remdesivir, hydroxychloroquine, lopinavir/ritonavir (andi-HIV drugs) and interferon - and to see if any had the
potential to being a "silver bullet" for 1st world and 2nd and 3rd world countries all over the world. And then other studies would know a direction to follow up.
I agree with the quote from the link within that states:
“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world.
We need scalable, affordable and equitable treatments.”
As to your statements:
"When I read this article I was alarmed by the emphasis that they placed on the drug cost instead of whether the drug works. The entire population of the world is not going to die from Covid prior to the vaccine (at least).
Why not give it to the people (all over the world) that develop the virus?"
MOO answer: Because it hasn't been proven to affect mortality. And to give it to people all over the world that develop the virus.... well, even if we had all the money in the world there wouldn't be resources to hospitalize them to give them all. The $$$$ to do such for the required infusions and cost for dosages would break the system. The reduction in anticipated hospitalizations would certainly focus on those that would be projected to have the worst outcomes MOO. And MOO that is a problem most of the studies have had. They are using antivirals perhaps TOO LATE in the cycle. That it takes a while to get folks in the studies, and then it's in the phase where it's not going to make a difference as it's in the destruction of the body and all the other happenings, when the anti-inflammatories perhaps are best suited? These things weren't known when the studies were intially set up perhaps to get folks on DAY 1 in a study.
Pfffft, how can that even happen to get someone in a study at the outset as that takes time to do, that folks don't get their test back soon enough etc. I have no answer to such.
There lies the quandry as these are now known to be best suited to give IMMEDIATELY during the initial replication phase, and only folks like Trump and Christie have had that opportunity that can be pinpointed as an example most here can relate to iykwim. Once the cascade has started in the second stage... it's showing that there is not an opportunity to be a silver bullet unless PERHAPS combined with a second stage intervention... e.g. the anti-inflammatories etc. MOO
As to the WHO study they found those 4 were not effective, although most ALL the studies were done perhaps too late in the viral cycle to affect outcomes. And now are moving onto monoclonal antibodies and immune-modulators, (which MOO is going to have the same issue... how can those be given to EVERY SINGLE PERSON during the viral replication stage prior to going into the second stage?... and at what cost???) and letting first world countries perhaps accept/reject the small thing that came out... e.g. that it reduced hospitalization.
3rd world countries don't have the capabilities to even consider that it's good that Remdesevir reduced the hospitalization stay a few days..and they perhaps don't have the capabilities to even have huge hospitalizations for folks in the first place (remdesevir required 5 or 10 days in hospital dosaging)
Additionally, the focus for the WHO is looking for treatments that have significant outcomes such as reductions in mortality. The study found none of these 4 treatments substantially affected mortality or reduced the need to ventilate patients.
"The unpromising overall findings from the regimens tested suffice to refute early hopes, based on smaller or non-randomized studies, that any will substantially reduce inpatient mortality, initiation of ventilation or hospitalisation duration
. Narrower confidence intervals would be helpful (particularly for Remdesivir), but the main need is for better treatments. Solidarity is still recruiting about 2000 patients per month, and efficient factorial designs will allow it to assess further treatments, such as immune-modulators and specific anti-SARS-Cov-2 monoclonal antibodies."
Ooops, I'll be back with links and 4+ ETAs for each...............brb
#1 ETA WHO study
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1.full.pdf
#2 MSM link from above which is a month late... but is hitting MSM now
WHO study finds remdesivir didn't help COVID-19 patients
#3 Remdesivir for the Treatment of Covid-19 — Final Report (NEJM) |
https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
#4 MedCram video, see links and comments
@margarita25 @10ofRods